- Home
- BL vs NAMS Comparison
BL vs NAMS Comparison
Compare BL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BL
- NAMS
- Stock Information
- Founded
- BL 2001
- NAMS 2019
- Country
- BL United States
- NAMS Netherlands
- Employees
- BL N/A
- NAMS N/A
- Industry
- BL Computer Software: Prepackaged Software
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BL Technology
- NAMS Health Care
- Exchange
- BL Nasdaq
- NAMS Nasdaq
- Market Cap
- BL 3.3B
- NAMS 3.1B
- IPO Year
- BL 2016
- NAMS N/A
- Fundamental
- Price
- BL $57.25
- NAMS $36.97
- Analyst Decision
- BL Buy
- NAMS Strong Buy
- Analyst Count
- BL 11
- NAMS 10
- Target Price
- BL $59.27
- NAMS $43.70
- AVG Volume (30 Days)
- BL 1.2M
- NAMS 1.2M
- Earning Date
- BL 11-06-2025
- NAMS 11-06-2025
- Dividend Yield
- BL N/A
- NAMS N/A
- EPS Growth
- BL 48.84
- NAMS N/A
- EPS
- BL 1.34
- NAMS N/A
- Revenue
- BL $674,325,000.00
- NAMS $64,006,000.00
- Revenue This Year
- BL $10.43
- NAMS N/A
- Revenue Next Year
- BL $8.78
- NAMS N/A
- P/E Ratio
- BL $42.81
- NAMS N/A
- Revenue Growth
- BL 8.00
- NAMS 762.15
- 52 Week Low
- BL $40.82
- NAMS $14.06
- 52 Week High
- BL $66.25
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- BL 68.60
- NAMS 58.95
- Support Level
- BL $56.45
- NAMS $35.50
- Resistance Level
- BL $58.45
- NAMS $39.03
- Average True Range (ATR)
- BL 2.05
- NAMS 2.30
- MACD
- BL 0.70
- NAMS -0.26
- Stochastic Oscillator
- BL 82.12
- NAMS 36.93
About BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.